Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0026838 (
spasticity
)
6,471
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In ten patients with para- or tetraspastic syndromes of various etiology 5 different spastic phenomena demonstrating pathologically raised excitability of muscle regulation functions were registered electromyographically before and 1 h after i.v. administration of N-(hydroxy-2-ethyl)-cinnamamide (
LCB
-29). In the majority of cases a marked decrease of
spasticity
was registered. The rapid onset of this effect of
LCB
-29 allowed constant test conditions and therefore eliminated other influences on
spasticity
. The decrease of raised polysynaptic excitability at spinal level led, at least in part, to the assumption of a spinal site of action of
LCB
-29. The absence of a sedative effect with oral medication makes a strong central effect seem less probable.
...
PMID:[Electromyographic studies on the effect of the cinnamamide derivative LCB-29 in spastic syndromes (author's transl)]. 57 57
